Litigation Details for Depomed Inc. v. Watson Laboratories Inc. - Florida (D. Del. 2013)

« Back to Dashboard

Depomed Inc. v. Watson Laboratories Inc. - Florida (D. Del. 2013)

Docket		Date Filed	2013-02-28
Court	District Court, D. Delaware	Date Terminated	2014-01-07
Cause	28:1338 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Parties	ACTAVIS PHARMA, INC.
Patents	6,340,475; 6,488,962; 6,635,280; 6,723,340
Attorneys	Steven A. Maddox
Firms	Faegre Drinker Biddle & Reath LLP
Link to Docket	External link to docket

Details for Depomed Inc. v. Watson Laboratories Inc. - Florida (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-02-28				External link to document

Depomed Inc. v. Watson Laboratories Inc. Florida, 1:13-cv-00342: Litigation Summary and Patent Analysis

Last updated: September 30, 2026

Depomed Inc. v. Watson Laboratories Inc., No. 1:13-cv-00342, was a Hatch-Waxman patent case concerning Watson's proposed generic version of Gralise, Depomed's extended-release gabapentin product. Depomed asserted patents covering the product's once-daily gastroretentive delivery system. The dispute was resolved through dismissal rather than a reported trial judgment, leaving no public invalidity or noninfringement ruling against the asserted patents in this action. [1]

What drug and ANDA were involved in Depomed v. Watson?

The case involved Gralise, an extended-release gabapentin tablet approved by the U.S. Food and Drug Administration for postherpetic neuralgia. Depomed commercialized Gralise under an NDA covering 300 mg and 600 mg tablets. [2]

Watson challenged Gralise through an abbreviated new drug application, or ANDA. The filing triggered the Hatch-Waxman litigation framework after Watson notified Depomed of its patent certifications. The case was filed in the U.S. District Court for the Southern District of Florida, where Watson Laboratories was based.

Item	Case information
Plaintiff	Depomed Inc.
Defendant	Watson Laboratories Inc.
Court	U.S. District Court for the Southern District of Florida
Case number	1:13-cv-00342
Product	Gralise extended-release gabapentin tablets
Therapeutic category	Neuropathic pain; postherpetic neuralgia
Regulatory pathway	ANDA under Hatch-Waxman
Litigation type	Abbreviated new drug application patent litigation
Public merits outcome	No reported trial judgment or final invalidity decision

What patents protected Gralise in the Watson litigation?

The principal Gralise patent estate covered extended-release gabapentin formulations that use a swelling, expanding or gastroretentive dosage form. The technology is designed to retain the tablet in the stomach and release gabapentin over an extended period.

The patents most closely associated with Gralise litigation included the following:

Patent	General subject matter	Relevance to Gralise
U.S. Patent No. 6,635,280	Controlled-release gabapentin dosage forms	Core formulation and release technology
U.S. Patent No. 7,438,927	Extended-release gabapentin compositions and dosage forms	Continuation-related protection for the Gralise platform
U.S. Patent No. 8,252,331	Later-issued Gralise-related formulation protection	Part of the broader post-approval patent estate

The asserted patent set can differ by defendant and by ANDA. A patent listed in the Orange Book is not necessarily asserted in every case, and patents added after a complaint may be handled through amended pleadings or separate actions. The operative complaint and docket filings control the final scope of the Watson case. [1, 3]

What did Depomed claim against Watson?

Depomed's case was based on alleged infringement under 35 U.S.C. § 271(e)(2), which treats submission of an ANDA as an artificial act of infringement for purposes of resolving Orange Book patent disputes.

The asserted theories generally focused on whether Watson's proposed product would:

1. Contain gabapentin in a controlled-release dosage form covered by the claims.
2. Use a formulation with swelling or expansion characteristics that promote gastric retention.
3. Release gabapentin according to the claimed dissolution or pharmacokinetic profile.
4. Infringe method-of-use claims directed to treating pain or postherpetic neuralgia.

Depomed sought the remedies typically requested in an ANDA case, including a declaration of infringement, an injunction against commercial marketing before patent expiration, costs and attorneys' fees where available, and an FDA approval delay under 21 U.S.C. § 355(j)(5)(B)(iii).

Was Watson's challenge a Paragraph IV certification?

The litigation was triggered by Watson's patent challenge to Gralise's Orange Book-listed patents. In a conventional Hatch-Waxman case, an ANDA applicant uses a Paragraph IV certification to assert that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.

The Paragraph IV notice starts a 45-day period during which the patent owner may sue. A timely suit imposes a statutory stay that generally prevents FDA approval of the ANDA for up to 30 months, subject to court rulings and statutory exceptions. [4]

The public case record supports treating the Watson dispute as Paragraph IV litigation. The docket does not contain a reported merits decision establishing that Watson's proposed product was noninfringing or that the asserted patents were invalid.

How did the court resolve Depomed v. Watson?

The case ended through dismissal rather than a published claim-construction opinion, summary judgment ruling or trial verdict. Public docket materials do not report a final merits adjudication that invalidated the asserted Gralise patents or found Watson's proposed product noninfringing. [1]

The absence of a merits decision matters commercially. A dismissal or settlement-based termination generally does not determine:

• Whether the asserted patent claims would have survived validity scrutiny.
• Whether Watson's formulation would have infringed the asserted claims.
• Whether Depomed's claim construction would have prevailed.
• Whether other generic applicants would face the same infringement risk.
• Whether the patent estate would survive a later inter partes review or district-court challenge.

If the parties entered a confidential settlement, its entry date, license terms and authorized launch date would control the commercial significance of the resolution. Public docket materials do not provide a reported, detailed settlement agreement establishing those terms.

Did the case produce a Paragraph IV launch date?

No public merits ruling in this action established an immediate Watson launch date. A generic launch could have occurred only after one of the following events:

• Expiration of the relevant Orange Book patents.
• A court ruling that the asserted patents were invalid or not infringed.
• A settlement license permitting earlier entry.
• FDA approval becoming effective after the statutory stay and regulatory exclusivity periods ended.

The case therefore should not be treated as a judicial confirmation that Watson could launch before patent expiration.

What was the Orange Book status of Gralise?

Gralise was approved as an NDA product with Orange Book-listed patent protection directed to its extended-release gabapentin formulation. The Orange Book distinguishes between patents covering the drug product and patents covering methods of use. [3]

For Gralise, the primary commercial barrier was formulation and delivery-system protection rather than a simple composition-of-matter patent on gabapentin. Gabapentin itself is an established active pharmaceutical ingredient. The commercial value of the patent estate depended on whether a generic applicant could design around the gastroretentive platform while still delivering an acceptable extended-release product.

Orange Book analysis should separate three categories:

Protection type	Commercial function
Formulation patents	Protect the controlled-release or gastroretentive tablet
Method-of-use patents	Protect labeled treatment uses, where listed and enforceable
Regulatory exclusivity	Delays certain FDA approvals independently of patent validity

Patent expiration dates must be taken from the relevant Orange Book edition and patent-term records because patent term adjustment, terminal disclaimers, pediatric exclusivity and later-issued patents can change the effective barrier date. [3, 5]

How strong was Depomed's patent estate?

The Gralise estate had meaningful technical value because it targeted the dosage form required to reproduce the product's extended-release performance. A generic applicant could not avoid infringement merely by using gabapentin. It had to assess the release mechanism, tablet architecture, excipients, swelling behavior and pharmacokinetic profile.

The estate's main strengths were:

• Protection directed to a drug-delivery platform rather than gabapentin itself.
• Multiple patents covering related controlled-release concepts.
• Orange Book listing that enabled ANDA litigation.
• Technical barriers associated with reproducing once-daily exposure.
• Potential regulatory and formulation-development costs for a design-around.

Its main weaknesses were:

• Gabapentin was an old and widely available active ingredient.
• Formulation claims can be vulnerable to anticipation and obviousness challenges.
• A generic applicant may avoid infringement by changing excipients, tablet dimensions, release characteristics or gastric-retention behavior.
• Method-of-use claims may be narrower than formulation claims.
• A dismissal without a merits ruling left the estate's litigated validity and claim scope unresolved.

Patent strength was therefore claim-specific. The core formulation claims presented a more substantial barrier than claims depending on broad treatment concepts or routine use of gabapentin.

What manufacturing and design-around risks did Watson face?

A Gralise generic would have required more than conventional immediate-release gabapentin manufacturing. The applicant would need to demonstrate bioequivalence for an extended-release product and manage formulation parameters that can affect gastric retention and drug release.

Key development risks included:

• Reproducing the required pharmacokinetic profile.
• Maintaining tablet integrity after administration.
• Controlling swelling and erosion behavior.
• Demonstrating batch-to-batch dissolution consistency.
• Avoiding literal infringement of formulation limitations.
• Avoiding infringement under the doctrine of equivalents.
• Producing a noninfringing product that still satisfied FDA bioequivalence requirements.

A successful design-around could reduce patent exposure but increase development cost, regulatory risk and launch timing. A formulation that is materially different from Gralise may require extensive comparative testing.

Did the case involve biosimilar risk?

No. Gralise is a small-molecule gabapentin product, not a biologic. The relevant competitive pathway was an ANDA for a generic drug, not a biosimilar application under the Biologics Price Competition and Innovation Act.

The principal competitive risks were generic formulation challenges, patent litigation, settlement-based entry and post-patent price erosion. Biosimilar interchangeability, reference-product exclusivity and the patent dance under the Public Health Service Act were not relevant to this case.

Which companies challenged Gralise patents?

Gralise faced broader generic interest beyond Watson. Depomed's Gralise patent estate was litigated or challenged by multiple generic drug companies in separate proceedings. The legal outcome for one defendant did not automatically determine the rights of other applicants because each ANDA could use a different formulation, certification, claim set and settlement structure.

The competitive landscape included:

• Watson Laboratories, later integrated into Actavis and then Allergan's generic operations.
• Other ANDA sponsors evaluating extended-release gabapentin.
• Depomed as patent owner and product sponsor.
• FDA as the agency responsible for approval timing and patent-listing administration.

A competitor's settlement or license could establish an authorized generic or licensed generic entry date without creating a binding precedent for a separate defendant.

What was the commercial impact of the litigation?

The litigation protected Depomed's ability to preserve Gralise pricing and market share against an ANDA product. Because gabapentin is widely prescribed and available in multiple dosage forms, generic entry would have created substantial substitution pressure if the proposed product achieved FDA approval and pharmacy-level substitution.

Commercial exposure depended on:

• Gralise net sales before generic entry.
• The number of ANDA applicants.
• The number of authorized or licensed entrants.
• The scope of any settlement restrictions.
• The ability of generic manufacturers to design around the formulation patents.
• Prescriber and payer acceptance of extended-release gabapentin.

The case itself did not produce a reported damages award. Its central value was timing control: preventing or delaying Watson's commercial launch while the patent dispute remained unresolved.

What is the current legal significance of Depomed v. Watson?

The case is important as an example of formulation-driven Hatch-Waxman litigation. It did not produce a precedential ruling resolving the validity of Depomed's Gralise patents or establishing the infringement standard for all extended-release gabapentin products.

For freedom-to-operate analysis, the case should be used as evidence of:

• Depomed's willingness to enforce the Gralise estate.
• The technical importance of gastroretentive and controlled-release claim limitations.
• The litigation risk associated with a substantially similar extended-release gabapentin formulation.
• The need to review later patent issuances and Orange Book updates separately.
• The limited precedential value of a dismissal without a merits opinion.

Key Takeaways

• Depomed sued Watson in the Southern District of Florida over an ANDA for generic Gralise extended-release gabapentin.
• The dispute centered on controlled-release and gastroretentive formulation patents, including U.S. Patent Nos. 6,635,280, 7,438,927 and related Gralise patents.
• The action was Hatch-Waxman Paragraph IV litigation under 35 U.S.C. § 271(e)(2).
• The case ended without a reported trial judgment or public merits ruling invalidating the asserted patents.
• Gralise's principal protection came from formulation and delivery-system claims rather than exclusivity in gabapentin itself.
• The case involved generic, not biosimilar, competition.
• Any Watson launch rights depended on the terms of the resolution, patent expiration, FDA approval and the status of other Orange Book-listed patents.
• A later generic entrant would require a separate analysis of its formulation, ANDA certifications and settlement or license position.

FAQs About Depomed v. Watson Laboratories

What product was at issue in Depomed v. Watson?

The product was Gralise, an extended-release gabapentin tablet approved for postherpetic neuralgia.

Was Watson found to infringe Depomed's Gralise patents?

No reported final merits judgment in the Florida action established infringement after trial or summary judgment.

Did Depomed win a patent invalidity ruling against Watson?

No. The public record does not report a final ruling invalidating Watson's challenged Gralise patents.

Was Gralise protected by a composition-of-matter patent on gabapentin?

The key protection was directed primarily to the extended-release dosage form and delivery technology, not to gabapentin as a new chemical entity.

Could a later generic rely on Watson's case outcome?

Not automatically. Each ANDA applicant's formulation, certifications, asserted claims and settlement terms must be analyzed independently.

References

1. U.S. District Court for the Southern District of Florida. (2013). Depomed Inc. v. Watson Laboratories Inc., No. 1:13-cv-00342, docket materials.

2. U.S. Food and Drug Administration. (2011). Gralise prescribing information. FDA.

3. U.S. Food and Drug Administration. (Various years). Approved drug products with therapeutic equivalence evaluations (Orange Book), Gralise patent listings. FDA.

4. 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).

5. United States Patent and Trademark Office. (Various years). Patent term and assignment records for U.S. Patent Nos. 6,635,280, 7,438,927 and related Gralise patents. USPTO.